WallStSmart
SAVA

Cassava Sciences Inc

NASDAQ: SAVA · HEALTHCARE · BIOTECHNOLOGY

$1.28
+0.00% today

Updated 2026-06-04

Market cap
$114.97M
P/E ratio
P/S ratio
2.54x
EPS (TTM)
$-2.22
Dividend yield
52W range
$1 – $5
Volume
0.4M

Cassava Sciences Inc (SAVA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-0.89%
ROA
-24.80%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$53.92M$6.19M100.00%-1.03%11.48%
2007$65.98M$20.30M100.00%15.41%30.77%
2008$63.73M$15.35M100.00%13.67%24.08%
2009$20.56M$-3.47M100.00%-32.85%-16.86%
2010$16.81M$-12.02M100.00%-81.52%-71.53%
2011$11.48M$-2.61M100.00%-30.60%-22.75%
2012$10.89M$-3.45M100.00%-35.79%-31.64%
2013$41.12M$31.54M100.00%76.28%76.71%
2014$-12.39M
2015$0.00$-14.14M
2016$0.00$-14.85M
2017$0.00$-11.91M
2018$0.00$-6.56M
2019$0.00$-4.25M
2020$0.00$-6.33M
2021$0.00$-31.80M
2022$-1800.00$-72.47M100.00%4,445,555.56%4,026,222.22%
2023$0.00$-97.22M
2024$0.00$-24.34M
2025$0.00$-90.97M

Frequently asked questions

How much free cash flow does SAVA generate?

SAVA produced $-32.83M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SAVA's balance sheet healthy?

SAVA holds $95.50M in cash and equivalents against — in long-term debt, on $74.40M of shareholder equity. That debt is best read against the cash flow the business throws off each year.